Biodesix (BDSX) 46th Annual William Blair Growth Stock Conference summary

Business performance and financial highlights

• Achieved over 40% revenue growth in Q1 and guided full-year revenue to $108M–$114M, representing 25% year-over-year growth.

• Maintained industry-leading gross margins above 80%, with a 300-basis point improvement year-over-year.

• Saw 29% growth in test volumes and 37% growth in lung diagnostic revenue for the quarter.

• Improved operational efficiency, reimbursement, and average revenue per test, with durable ASP gains.

• On track to achieve cash flow positivity and profitability by year-end.

Commercial strategy and market expansion

• Built a robust commercial infrastructure targeting pulmonologists and primary care, with 50 sales territories.

• Focused on execution and leveraging established market leadership for future organic and inorganic growth.

• Identified 15,000 primary care physicians managing 80% of pulmonary nodules, making outreach highly targeted.

• Expanded sales roles to include general practice consultants for primary care, driving adoption of Nodify tests.

• Leveraged key opinion leaders to educate referral networks and accelerate test adoption.

Product innovation and clinical impact

• Nodify Lung portfolio addresses risk stratification for 5–6 million patients with lung nodules annually.

• Proprietary tests with ADLT status provide pricing control and protection.

• Tests enable earlier detection and triage of high-risk patients, improving outcomes and reducing unnecessary procedures.

• Data visualization tools demonstrate clinical utility and drive adoption among physicians.

• Published the largest clinical validation study for a lung nodule biomarker and continue to expand evidence base.